IGF-2 Peptide Priming for Less Frequent Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 1 and type 2 diabetes, require daily insulin injections, which are inconvenient and costly, and can cause side effects, while gestational diabetes often resolves post-birth.
Innovation Solution
Administration of insulin-like growth factor 2 (IGF-2) or variants thereof in specific doses over several days to regulate blood glucose levels and increase insulin production, potentially eliminating the need for daily insulin therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If daily insulin injections are administered to treat diabetes, then blood glucose levels are controlled, but treatment convenience deteriorates and side effects increase
Solution Approach 1:
The patent employs a priming dose regimen where initial daily IGF-2 injections (administered for 3-7 days) prepare the body by stimulating endogenous insulin production and upregulating IGF-2 receptors. This preliminary action enables subsequent transition to less frequent dosing (every 2-4 weeks), thereby achieving long-term glucose control without daily injections. The priming phase lays the physiological foundation that eliminates the need for continuous daily treatment.
Solution Approach 2:
The patent utilizes parameter changes by administering IGF-2 at specific dosages (65-1626 μg/kg body weight) that trigger a physiological response - specifically, stimulation of pancreatic beta cells to produce endogenous insulin. This parameter change (from exogenous insulin replacement to endogenous insulin production) fundamentally alters the treatment mechanism, improving convenience while maintaining glucose control efficacy.
2Reliability
If daily insulin injections are administered to treat diabetes, then blood glucose levels are controlled, but treatment cost increases
Solution Approach 1:
The priming dose phase (3-7 days of daily injections) is an investment that stimulates the body's own insulin production capacity. Once this physiological change is achieved, the body produces endogenous insulin that continues to regulate glucose levels without requiring continuous exogenous insulin administration. This reduces the quantity of insulin medication needed over time, thereby lowering treatment costs while maintaining glucose control.
Solution Approach 2:
The patent enables the patient's own body to produce and regulate insulin through IGF-2 stimulation of pancreatic beta cells. This self-service mechanism (endogenous insulin production) replaces the need for continuous exogenous insulin administration, reducing both the quantity of medication required and the associated treatment costs while maintaining effective glucose control.
3Reliability
If daily insulin injections are administered to treat diabetes, then blood glucose levels are controlled, but side effects increase
Solution Approach 1:
IGF-2 serves as an intermediary substance that indirectly stimulates endogenous insulin production rather than directly administering insulin. This intermediary mechanism (IGF-2 → beta cell stimulation → endogenous insulin) avoids the direct side effects of exogenous insulin therapy such as hypoglycemia, weight gain, and injection site reactions. The intermediary approach achieves glucose control while minimizing harmful effects.
Solution Approach 2:
By stimulating the body's own insulin production system rather than replacing it with exogenous insulin, the treatment avoids the side effects associated with external insulin administration. The endogenous insulin produced in response to IGF-2 stimulation maintains physiological regulation patterns, thereby reducing side effects such as hypoglycemia and weight gain while maintaining effective glucose control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
IGF-2 effectively lowers and maintains blood glucose levels at normal ranges, increases insulin production, and prevents the onset of diabetes, providing long-term treatment without daily injections and side effects.
Implementation Method 1
IGF-2 is a peptide hormone that is structurally related to insulin and that binds to the insulin receptor and activates signal transduction pathways
Data Source
AI summary
The disclosure provides for peptides, fragments, compounds, compositions, and methods of use thereof for treating diabetes (e.g., type 1 diabetes, type 2 diabetes). In some aspects, methods comprise administering peptides, fragments, or a variant thereof to the subject for treating diabetes and diseases related to diabetes. In other aspects, compounds, compositions, and methods containing IGF-2 or variants thereof, IGF-2 peptides, and IGF-2 fragments are used for treating a disorder in a patient in need thereof, such as type 1 or type 2 diabetes.